Andreas Almlen
Overview
Explore the profile of Andreas Almlen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almlen A, Vandenbussche G, Linderholm B, Haegerstrand-Bjorkman M, Johansson J, Curstedt T
Biochim Biophys Acta
. 2011 Feb;
1818(1):27-32.
PMID: 21284935
The secondary structure, orientation and hydrogen/deuterium exchange of SP-C33, a surfactant protein C analog, in 1,2-dipalmitoyl-sn-glycero-3-phosphocholine/egg phosphatidylglycerol (8:2, wt./wt.) bilayers, was studied by attenuated total reflection Fourier transform infrared spectroscopy....
2.
Almlen A, Walther F, Waring A, Robertson B, Johansson J, Curstedt T
Neonatology
. 2010 Jan;
98(1):91-9.
PMID: 20110733
Background: Respiratory distress syndrome (RDS) is currently treated with surfactant preparations obtained from natural sources and attempts to develop equally active synthetic surfactants have been unsuccessful. One difference in composition...
3.
Stichtenoth G, Linderholm B, Almlen A, Bjorkman M, Byman I, Nordling K, et al.
Crit Care Med
. 2009 Mar;
37(5):1750-6.
PMID: 19325472
Objective: Surface activity of pulmonary surfactant is impaired by exposure to syringes lubricated with silicone oil (SO). These syringes are used daily in clinical practice. Design: In vitro experiments were...
4.
Almlen A, Stichtenoth G, Linderholm B, Haegerstrand-Bjorkman M, Robertson B, Johansson J, et al.
J Appl Physiol (1985)
. 2008 Feb;
104(4):1101-8.
PMID: 18276900
Modified natural surfactant preparations, used for treatment of respiratory distress syndrome in premature infants, contain phospholipids and the hydrophobic surfactant protein (SP)-B and SP-C. Herein, the individual and combined effects...
5.
Almlen A, Stichtenoth G, Robertson B, Johansson J, Curstedt T
Neonatology
. 2007 May;
92(3):194-200.
PMID: 17476119
Background: Modified natural surfactants currently used for treatment of respiratory distress syndrome contain about 0.5-1% (w/w phospholipids) of each of the surfactant proteins SP-B and SP-C. The supply of these...
6.
Li J, Liepinsh E, Almlen A, Thyberg J, Curstedt T, Jornvall H, et al.
FEBS J
. 2006 Feb;
273(5):926-35.
PMID: 16478467
Mature lung surfactant protein C (SP-C) corresponds to residues 24-58 of the 21 kDa proSP-C. A late processing intermediate, SP-Ci, corresponding to residues 12-58 of proSP-C, lacks the surface activity...
7.
Johansson J, Some M, Linderholm B, Almlen A, Curstedt T, Robertson B
J Appl Physiol (1985)
. 2003 Aug;
95(5):2055-63.
PMID: 12897027
Available surfactants for treatment of respiratory distress syndrome in newborn infants are derived from animal lungs, which limits supply and poses a danger of propagating infectious material. Poly-Val-->poly-Leu analogs of...